PPT-Dual Antiplatelet Therapy (DAPT) Duration

Dilemma Recent Trials And Guidelines For Clinical Practice Dean J Kereiakes MD FACC FSCAI Medical Director The Christ Hospital Heart amp Vascular Center and the Lindner Research Center at The Christ Hospital Cincinnati Ohio. Antiplatelet Guidelines. Antiplatelet. Therapy for . Vascular Prevention in Patients with Peripheral Arterial Disease. Working. Group. : A. Roussin, MD, FRCP; Thomas F. Lindsay, MD, CM. , FRCSC. Objectives. Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. What Has Changed?. Less Stent Thrombosis . With. . New-Generation DES. What Are the Results of the Randomized Trials on the Duration of DAPT After Stenting?. Shorter Duration of DAPT Trials. DAPT Study. Evidence-Based Antiplatelet Therapy Across the ACS Spectrum Panelists Program Goals Case Study Case Study (cont) Presenting ECG Guideline for Urgent/Immediate Invasive Strategy (1A Recommendation) An Immediate Invasive Strategy A ssessment of D ual antiplatelet therapy versus R ivaroxaban I n atrial F ibrillation patients T reated with left atrial appendage closure ADRIFT investigators DOI public at www.action-coeur.org R. ivaroxaban . I. n atrial . F. ibrillation patients . T. reated with left atrial appendage closure. ADRIFT . investigators. DOI public at www.action-coeur.org. Healing: 30 . days. to 3 . months. Kar et al. JACC Intv 2014;7:801-9. (DAPT) . BHAVI SHAH, DNP, APRN, ANP-C. UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER. DEPARTMENT OF MEDICINE. CARDIOLOGY SECTION. WHAT REALLY HAPPENS . Normal endothelium regulates blood flow. Tissue Injury . Anticoagulant therapy. (n = . 124). CADISS. P. rimary outcome. : . Ipsilateral . stroke or all-cause mortality . for antiplatelet vs. anticoagulation: 2. % . vs. 1%; p . = . 0.63. Any stroke: 2% vs. 1%, . , MD. , PhD. Professor. of Medicine. Medical Director - Cardiovascular . Research. Program. Director – . Interventional. . Cardiology. . Fellowship. University. of Florida . College. of Medicine - Jacksonville. 12. inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study. Luis Ortega-Paz, MD, PhD. 1. ; Francesco Franchi, MD. intracerebral haemorrhage (ICH): extended follow-up of the. RE. start. or . ST. op. . A. ntithrombotics. . R. andomised . T. rial. (RESTART) . RESTART Collaboration. www.RESTARTtrial.org. Intracerebral haemorrhage (ICH) is associated with an increased risk of arterial ischaemic events*: pooled analysis of 4 population-based cohorts. Hyeon-Cheol . Gwon. , . Joo. Yong Hahn, Young Bin Song,. Kyung Woo Park, Yang . Soo. Jang, . Hyo-Soo. Kim,. O. n behalf of the EXCELLENT Trial Investigators. Samsung Medical Center, Sungkyunkwan University School of Medicine.